Philips and Ibex Medical Analytics team to accelerate adoption of
AI-powered digital pathology
April 8, 2021
- Philips and Ibex Medical Analytics cooperate to globally
commercialize clinically proven, AI-powered digital pathology
solutions
- Combination of Philips’ digital pathology solutions and Ibex’s
AI-powered Galen platform has improved reporting efficiency by 27%,
driven 37% productivity gains, and improved consistency and
accuracy to enhance diagnostic confidence
- Collaboration furthers Philips’ commitment to integrated
diagnostics providing a clear path to precision
diagnosis
Amsterdam, The Netherlands and Tel Aviv, Israel
– Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in
health technology, and Ibex Medical Analytics, a pioneer in
artificial intelligence (AI) based cancer diagnostics, today
announced a strategic collaboration to jointly promote their
digital pathology and AI solutions to hospitals, health networks
and pathology labs worldwide. The combination of Philips digital
pathology solution (Philips IntelliSite Pathology Solution) and
Ibex’s Galen™ AI-powered cancer diagnostics platform [1], currently
in clinical use in Europe and the Middle East, empowers
pathologists to generate objective, reproducible results, increase
diagnostic confidence, and enable the productivity and efficiency
improvements needed to cope with ever-increasing demand for
pathology-based diagnostics.
Today’s announcement marks the latest extension to Philips’
AI-enabled Precision Diagnosis solutions portfolio, which leverages
Philips and third-party AI solutions to deliver cutting-edge
clinical decision support and optimized workflows that enable
healthcare providers to deliver on the Quadruple Aim of better
patient outcomes, improved patient and staff experiences, and lower
cost of care.
The trend towards centralized pathology labs, the global
shortage of trained pathologists, and increasing demands on
histopathology posed by the growing number of cancer patients,
leads pathology labs to actively seek efficiency-enhancing
solutions that enable to maintain high accuracy levels. Digital
pathology, enabled by solutions such as Philips IntelliSite
Pathology Solution has already been shown to improve pathology lab
productivity by 25% [2], while also allowing remote image reading
by specialists and the immediate sharing of images with referring
hospitals as part of comprehensive pathology reports. Ibex’s
AI-powered Galen platform further streamlines workflow and improves
accuracy via automated case prioritization, cancer heatmaps,
grading and other productivity-enhancing tools.
“Building on our strong portfolio to support clinical
decision-making in oncology, we bring together the power of
imaging, pathology, genomics and longitudinal data with insights
from artificial intelligence (AI) to help empower clinicians to
deliver clear care pathways with predictable outcomes for every
patient,” said Kees Wesdorp, Chief Business Leader, Precision
Diagnosis at Philips. “By teaming with Ibex to incorporate their AI
into our Digital Pathology Solutions, we’re further able to provide
a continuous pathway, where critical patient data is made visible
to both pathologists and oncologists to help improve the clinician
experience and patient outcomes.”
“Pathology is transforming at an increasing pace and AI is one
of the major drivers, supporting a more rapid and accurate cancer
diagnosis,” said Joseph Mossel, CEO and Co-founder of Ibex Medical
Analytics. “By joining forces with Philips, the leader in digital
pathology deployments, we can offer new end-to-end solutions
enabling pathologists to implement integrated, AI-powered workflows
across a broader segment of the diagnostic pathway, improving the
quality of patient care and strengthening the business case for
digitization.”Ibex’s Galen platform adds AI-powered cancer
detection, case prioritization, grading and other
productivity-enhancing insights. Users have reported significant
improvements in diagnostic efficiency, with 27% reduction in
time-to-diagnosis compared to conventional microscope viewing, 1-
to 2-day reductions in total turnaround time, and 37% productivity
gain [3]. In addition to cancer, the AI platform supports
pathologists in the accurate grading, as well as detection and
diagnosis of multiple clinical features, such as tumor size,
perineural invasion, high-grade PIN (Prostatic Intraepithelial
Neoplasia) and more. The accuracy level of Galen Prostate for
cancer detection was the highest level reported in the field, with
a sensitivity rate of 98.46%, specificity of 97.33% and an AUC of
0.991 [4]. When used as an automated ‘second read,’ the platform
alerts pathologists when discrepancies between their diagnosis and
the AI algorithm’s findings are detected, providing a safety net
against error or misdiagnosis, previously reported as high as 12%
[5], and increasing overall quality of care.
“We have been using Philips’ IntelliSite Pathology Solution
together with Ibex’s Galen™ platform as part of our routine
practice since 2020, and this ‘second read’ implementation has
already helped us improve our diagnostic quality,” said Delphine
Raoux, MD, pathologist and Head of Innovation Technologies at
Medipath, the largest network of private pathology labs in France.
“The work we presented recently showed that Ibex’s AI platform can
further provide significant productivity gains when used during
primary diagnosis and helps us reduce total turnaround time. This
is an important step forward as we look for new technologies that
can help meet an increasing demand for pathology services and could
enable seamless remote reading of biopsies in times of COVID
restrictions.”
Philips digital pathology solution is a comprehensive turnkey
solution that helps to speed and simplify access to histopathology
information across cancer care and beyond, supports full-scale
digitization of histology in pathology labs and lab networks, and
help increases workflow efficiency. At the heart is Philips
IntelliSite Pathology Solution, which comprises an ultra-fast
pathology slide scanner, an image management system and display
[6], which includes advanced software tools to manage slide
scanning, image storage, case review, and the sharing of patient
information. By fully digitizing post-sample-preparation
histopathology, it facilitates the streamlining of pathology
workflows and enables the connectivity needed between
multi-disciplinary teams and specialties when making complex cancer
diagnosis and treatment decisions, from early detection and
precision diagnosis through to precision treatment and predictable
outcomes.
Through breakthrough innovations and partnerships, Philips
integrates intelligence and automation into its Precision Diagnosis
portfolio, including smart diagnostic systems, integrated workflow
solutions that transform departmental operations, advanced
informatics that provides diagnostic confidence, and care pathway
solutions that allow medical professionals to tailor treatment to
individual patients. By developing and integrating these AI-enabled
applications, the company aims to enhance the ability to turn data
into actionable insights and drive the right care in the right
sequence at the right time.
Today’s partnership announcement with Ibex follows recent AI
partnership announcements with DiA Imaging Analysis for AI-powered
ultrasound applications, and AI software provider Lunit,
incorporating its chest detection suite into Philips diagnostic
X-ray suite. These partner solutions complement Philips own AI
solutions in personal health, precision diagnosis and treatment,
and connected care.
[1] Galen Prostate is CE marked and approved in additional
territories. Galen Prostate is not FDA approved and is for Research
Use Only (RUO) in the United States. [2] Survey with 52 physicians
in Europe, 2018. Results are specific to the institution where they
were obtained and may not reflect the results achievable at other
institutions.[3] Raoux D, et al, Novel AI Based Solution for
Supporting Primary Diagnosis of Prostate Cancer Increases the
Accuracy and Efficiency of Reporting in Clinical Routine
https://uscap.econference.io/public/fYVk0yI/main/sessions/9644/31166[4]
The LANCET Digital Health, Aug 2020, Pantanowitz et al, An
artificial intelligence algorithm for prostate cancer diagnosis in
whole slide images of core needle biopsies: a blinded clinical
validation and deployment study
https://www.thelancet.com/journals/landig/article/PIIS2589-7500(20)30159-X/fulltext[5]
Laifenfeld D et al, Performance of an AI-based cancer diagnosis
system in France’s largest network of pathology institutes
https://ibex-ai.com/wp-content/uploads/2019/09/poster-v6-web.pdf[6]
The display is part of the medical device in the United States.
For further information, please contact:
Kathy O’ReillyPhilips Global Press OfficeTel.: +1
978-221-8919E-mail : kathy.oreilly@philips.comTwitter:
@kathyoreilly
Tal FriemanIbex Medical AnalyticsTel.: +972
50-515-2195E-mail : tal.frieman@ibex-ai.com
About Royal PhilipsRoyal Philips (NYSE: PHG,
AEX: PHIA) is a leading health technology company focused on
improving people's health and well-being, and enabling better
outcomes across the health continuum – from healthy living and
prevention, to diagnosis, treatment and home care. Philips
leverages advanced technology and deep clinical and consumer
insights to deliver integrated solutions. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2020
sales of EUR 19.5 billion and employs approximately 82,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
About Ibex Medical AnalyticsIbex uses AI to
develop clinical-grade solutions that help pathologists detect and
grade cancer in biopsies. The Galen™ platform is the first-ever
AI-powered cancer diagnostics solution in routine clinical use in
pathology and deployed worldwide, empowering pathologists to
improve diagnostic accuracy, integrate comprehensive quality
control and enable more efficient workflows. Ibex’s solutions are
built on Deep Learning algorithms trained by a team of
pathologists, data scientists and software engineers. For more
information, go to www.ibex-ai.com
- Philips IntelliSite Pathology Solution 4.1
- Philips Digital Pathology
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Apr 2023 to Apr 2024